In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BSD-2000 PMA

This article was originally published in The Gray Sheet

Executive Summary

BSD Medical submits premarket approval application for tumor hyperthermia therapy May 22. The PMA is based on data from approximately 4,000 treatments of more than 800 patients (1"The Gray Sheet" Jan. 19, 2006, p. 15). The device employs an array of radiofrequency antennae to generate enough energy to target and kill cancer cells...

You may also be interested in...



Heat therapy for cancer

High-risk soft tissue sarcoma patients treated with BSD Medical's BSD-2000 hyperthermia system in addition to chemotherapy had nearly double the median time of disease free-survival (31.7 months) and local progression-free survival (45.3 months) compared with those only receiving chemotherapy, according to study results presented June 4 at the American Society of Clinical Oncology conference in Chicago. The 340-patient randomized trial was based on the belief that precision-focused, mild heating of cancer improves blood flow and leads to better absorption of chemotherapy drugs, in addition to directly killing cancer cells and improving chemical reactions of some drugs. BSD Medical submitted a PMA application for the BSD-2000 in May 2006 (1"The Gray Sheet" May 29, 2006, In Brief)...

BSD Medical Plans To File PMA For Cancer Therapy, Prepares Japanese Strategy

BSD Medical plans to submit a PMA application by the end of the quarter for its non-invasive BSD-2000 tumor hyperthermia therapy system to treat cancer

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

UsernamePublicRestriction

Register

MT023584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel